New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
07:59 EDTOHRPOhr Pharmaceutical negative report was misleading, says Brean Capital
Brean Capital believes last week's negative report on Ohr Pharmaceuticals was misleading. The firm believes its squalamine eye drops will be effective and expects the company to enter a joint venture to further develop it trodusquemine drug for yet undisclosed new indications. Shares are Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Check below for free stories on OHRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OHRP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use